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Abstract
Background
Post-exercise heart rate recovery (HRR) is an index of parasympathetic function associated
with clinical outcome in patients with chronic heart failure. However, its relationship with the
pro-inflammatory response and prognostic value in consecutive patients with acute decom-
pensated heart failure (ADHF) has not been investigated.
Methods
Wemeasured HRR and pro-inflammatory markers in 107 prospectively and consecutively
enrolled, recovered ADHF patients (71 male, 59 ± 15 years, mean ejection fraction 28.9 ±
14.2%) during the pre-discharge period. The primary endpoint included cardiovascular (CV)
events defined as CV mortality, cardiac transplantation, or rehospitalization due to HF
aggravation.
Results
The CV events occurred in 30 (28.0%) patients (5 cardiovascular deaths and 7 cardiac
transplantations) during the follow-up period (median 214 days, 11–812 days). When the
patients with ADHF were grouped by HRR according to the Contal and O’Quigley’s method,
low HRR was shown to be associated with significantly higher levels of serummonokine-
induced by gamma interferon (MIG) and poor clinical outcome. Multivariate Cox regression
analysis revealed that low HRR was an independent predictor of CV events in both enter
method and stepwise method. The addition of HRR to a model significantly increased
predictability for CV events across the entire follow-up period.
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Conclusion
Impaired post-exercise HRR is associated with a pro-inflammatory response and indepen-
dently predicts clinical outcome in patients with ADHF. These findings may explain the rela-
tionship between autonomic dysfunction and clinical outcome in terms of the inflammatory
response in these patients.
Introduction
Autonomic imbalance in heart failure is characterized by increased sympathetic activity and
withdrawal of parasympathetic activity. This autonomic imbalance is associated with progres-
sion of heart failure and a worse clinical outcome [1]. While beta-blockers have found a place
as a leading disease-modifying therapy that impacts the sympathetic nervous system, far less is
known about the withdrawal of parasympathetic activity. Moreover, it is difficult to measure
parasympathetic function directly. Parasympathetic activity can be measured crudely by exam-
ining responses to vagal nerve stimulation or pharmacologic blockade, heart rate variability,
and post-exercise heart rate recovery (HRR) [2].
Among these, post-exercise HRR provides a non-invasive and clinically feasible method to
quantitatively assess parasympathetic function. Impaired heart rate deceleration after exercise
cessation is associated with poor clinical outcome in subjects referred for exercise testing
regardless of cardiovascular disease history [3–5] or in patients with chronic heart failure [6–
11]. However, its prognostic value has not been confirmed in prospectively and consecutively
enrolled acute decompensated heart failure (ADHF) patients. Moreover, the underlying mech-
anism of how impaired HRR is associated with poor clinical outcome is not well understood.
One contributing factor could be that impaired HRR appears to correlate with an excessive
pro-inflammatory status. According to the recent concept of ‘cholinergic anti-inflammatory
pathway’, immunity is coordinated by neural circuits that operate reflexively, and this well-
established neural circuit terminates excessive pro-inflammatory cytokine responses, prevent-
ing immune-mediated damage [12,13]. Therefore, decreased parasympathetic activity may
result in pro-inflammatory responses and increased morbidity and mortality [14–16]. Thus,
we evaluated the prognostic value of post-exercise HRR, which is an index of parasympathetic
function, in relation with the pro-inflammatory response in prospectively and consecutively
enrolled, recovered ADHF patients.
Methods
Study population
Patients who were diagnosed with ADHF at Severance Cardiovascular Hospital were prospec-
tively and consecutively enrolled between May 2012 and April 2014. Patients who displayed
rapid onset of signs or symptoms of heart failure and one of the following criteria were eligible
for the study: (i) lung congestion or (ii) objective findings of left ventricular systolic dysfunc-
tion or structural heart disease. Lung congestion was defined as ‘congestion’ on a chest X-ray
or as rales on physical examination. Recovered ambulatory ADHF patients during hospitaliza-
tion were eligible for the study. Patients who could not perform the cardiopulmonary exercise
test (CPET) were excluded from this study. The primary endpoint included cardiovascular
(CV) events defined as a composite of death, rehospitalization due to worsening heart failure,
or urgent cardiac transplantation.
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Ethics statement
The study protocol was approved by the institutional review board (IRB) of Yonsei University
College of Medicine, Severance Hospital, Seoul, Republic of Korea and IRB number was 4-
2012-0027. All subjects provided written informed consent to participate in this study.
Biochemical and echocardiographic analysis
Blood samples were obtained after an 8-h overnight fast by venipuncture into plain and EDTA
tubes. Complete blood count, serum sodium, total cholesterol, albumin and serum creatinine
(Cr) were measured using standard automated laboratory techniques. The blood samples were
tested with NT-proBNP, which was kept at 4°C, using an electrochemiluminescence immuno-
assay (Elecsys proBNP; Roche Diagnostics, Basel, Switzerland); intra- and inter-assay coeffi-
cients of variations (CVs) were<1.3% and<1.7%, respectively. Plasma high sensitivity C-
reactive protein (hsCRP) levels were measured using an immunonephelometric method on a
BNII analyzer (Dade-Behring, Germany) with the manufacturer’s reagents. The detection limit
for hsCRP was 0.2 mg/L; intra- and inter-assay CVs were<5%, respectively.
Almost all echocardiographic measurements were performed at a relatively consistent time
point for the entire cohort, that is, on the day of admission or the day after admission. Left ven-
tricular ejection fraction (LVEF) was measured using the modified Quinones method. In
patients with regional wall motion abnormalities, the LVEF was calculated using Simpson’s
biplane method with apical four- and two-chamber views.
Cytometric bead array
We tried to assess the relationship between levels of pro-inflammatory markers and clinical
outcome in relation with HRR in this study. Blood for measuring various pro-inflammatory
chemokines was drawn on the day of or before discharge, at about the same time as the CPET
measurements. The concentrations of various serum chemokine markers (monokine-induced
by gamma interferon [MIG] (intra- and inter-assay CVs; 8.7% and 5.2%, respectively), inter-
feron gamma-induced protein 10 [IP-10] (intra- and inter-assay CVs; 4.0% and 4.0%, respec-
tively), chemokine (C-X3-C motif) ligand 1 [CX3CL1] (intra- and inter-assay CVs; 2.0% and
3.0%, respectively), monocyte chemotactic protein 1 [MCP1] (intra- and inter-assay CVs; 4.0%
and 6.9%, respectively), macrophage inflammatory protein 1α [MIP1α] (intra- and inter-assay
CVs; 4.0% and 4.0%, respectively), macrophage inflammatory protein 1β [MIP1β] (intra- and
inter-assay CVs; 3.0% and 3.0%, respectively), regulated on activation normal T cell expressed
and secreted [RANTES] (intra- and inter-assay CVs; 6.0% and 4.2%, respectively)), granzyme
B (intra- and inter-assay CVs; 2.0% and 5.0%, respectively), and tumour necrosis factor-α
(TNF-α) (intra- and inter-assay CVs; 6.0% and 8.0%, respectively) were measured by flow
cytometry using the BD cytometric bead array technique. Sample processing was performed
according to the manufacturer-supplied instructions (BD Biosciences, San Jose, CA). Briefly,
50 μl of mixed capture beads and 50 μl of each serum sample were incubated for 1 h at room
temperature (RT). Next, 50 μl of mixed phycoerythrin detection reagents were added to the
bead-sample mixture and incubated for 2 hour at RT. The samples were washed and assessed
with an LSR II Flow Cytometer (BD Biosciences, San Jose, CA). The data were analysed with
FlowJo software version 9.2 for Mac (TreeStar, Ashland, OR).
Assessment of post-exercise heart rate recovery (HRR)
A symptom-limited CPET was performed on a treadmill according to the modified Bruce ramp
protocol. The CPET was performed after “clinical stabilization” according to current medical
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guidelines. Clinical stabilization was defined as readiness for discharge from the hospital. Con-
gestion was absent, and a stable, oral diuretic regimen was established for at least 48 hours. The
CPET was performed at a relatively consistent time point, that is, on the day of or before dis-
charge. Patients were strongly encouraged to achieve a peak respiratory exchange ratio (RER)>
1.10. Expired gases were collected continuously throughout exercise and analysed for ventilator
volume, oxygen (O2) content, and carbon dioxide (CO2) content using a calibrated metabolic
cart (Quark CPET, COSMED, Chicago, IL, USA). Expired gases were reported every 15 sec-
onds. During the exercise test, monitoring consisted of continuous 12-lead electrocardiography,
manual blood pressure measurements and heart rate recordings at every stage. CPET was ter-
minated according to the following criteria: patient request, ventricular tachycardia,2 mm of
horizontal or down-sloping ST segment depression, or a drop in systolic blood pressure20
mm/Hg during exercise. A qualified exercise physiologist conducted each test with the supervi-
sion of a physician. The following variables were derived from the CPET results: peak oxygen
consumption (peak VO2); peak RER, defined by the ratio of CO2 production to O2 consump-
tion at peak effort; VE/VCO2 slope, defined as the slope of the increase in peak ventilation/
increase in CO2 production throughout exercise. After completion of exercise, the treadmill was
stopped within 20 seconds and all subjects recovered in a seated position. HRR was calculated
as the difference between heart rate at peak exercise and after 1 or 2 minutes of recovery after
CPET. Because there have been no reports regarding HRR in ADHF patients, we analysed both
HRR(1 min) and HRR(2 min) in this study.
Statistical analysis
Continuous variables are summarized as the mean ± standard deviation. Categorical variables
are summarized as a percentage of the total group. Discrete variables were compared using the
chi-squared method. Regarding the cut-off value of the post-exercise HRR, we chose a cut-off
point according to the Contal and O’Quigley's method [17] to maximize the hazard ratio (HRR
[1 min]< 13, HRR[2 min]< 27). The cumulative incidence of CV events was assessed with the
Kaplan-Meier method. The statistical significance of the curves was calculated using the log-
rank test. Univariate and multivariate Cox regression analysis were performed to identify inde-
pendent predictors of CV events in patients with ADHF. Because HRR(1min) and HRR(2min)
do not show normal distribution even after logarithmic transformation, we analysed HRR
(1min) and HRR(2min) as a categorical variables in Cox regression analysis. In enter method
multivariate Cox regression analysis, all significant variables in the univariate Cox analysis were
included to adjust relevant variables as many as possible. In addition, stepwise method multi-
variate Cox regression analyses were also performed to evaluate the independent associations of
HRR(1min) and HRR(2min) with the most relevant minimum variables to avoid the over-fit-
ting. We compared a model with HRR (full model) to a model without HRR (reduced model)
using the likelihood ratio test. To further evaluate the predictability of HRR across the entire
follow-up period, we applied a time-dependent ROC curve method for censored CV events
data. We then compared the global concordance probability (integrated area under the curve,
iAUC) of the model with HRR(1 min) and HRR(2 min) to that of the model without HRR.
iAUC is a weighted average of the area under the curve (AUC) across a period of follow-up that
measures the predictive accuracy of a model during that period. The differences and 95% confi-
dence interval were calculated by bootstrapping method. Two-sided p values of less than 0.05
and excluding 0 in the 95% confidence interval were considered to indicate statistical signifi-
cance. All statistical analyses were performed with SPSS version 20.0 (IBM Corporation,
Armonk, NY, USA), SAS (version 9.2, SAS Inc., Cary, NC, USA), and the R Statistical Package
(Institute for Statistics and Mathematics, Vienna, Austria, ver. 3.1.2, www.R-project.org).
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Results
Baseline characteristics of study subjects according to CV events
The CV events occurred in 30 (28.0%) patients (5 cardiovascular deaths and 7 cardiac trans-
plantations) during the follow-up period (median 214 days, 11–812 days). Clinical characteris-
tics, echocardiographic, laboratory, and cardiopulmonary exercise test parameters of the 107
ADHF patients studied (71 male, 59 ± 15 years, mean ejection fraction 28.9 ± 14.2%) are sum-
marized in Table 1 according to CV events. Patients with CV events were more likely to exhibit
exacerbated chronic HF rather than de novo HF, showed significantly lower BMI, hemoglobin
level, and higher NT-proBNP. The beta-blocker prescription rate of patients with CV events
was lower than that of patients without CV events. CPET parameters, including HRR(1 min)
and HRR(2 min), differed significantly between the two groups. Various markers for the pro-
inflammatory response, including MIG, IP-10, CXCL1, MCP-1, MIP1α, MIP1β, RANTES,
granzyme B, and TNF-α, showed no significant differences between patients with and without
CV events.
Prognostic value of HRR in relation to markers for the pro-inflammatory
response
We evaluated whether HRR is associated with the pro-inflammatory response and clinical out-
comes in ADHF patients. When ADHF patients were divided by HRR based on Contal and
O’Quigley's method, we found that Ln MIG, which is a T cell chemokine was significantly
higher in both the low HRR(1 min) (HRR[1 min]< 13) and low HRR(2 min) groups (HRR[2
min]<27) (HRR[1 min], 7.40 ± 1.10 pg/mL vs. 6.62 ± 1.02 pg/mL, p = 0.006; HRR[2 min],
7.42 ± 1.14 pg/mL vs. 6.78 ± 1.03 pg/mL, p = 0.024). Other pro-inflammatory markers showed
no significant differences relative to HRR group. Ln hsCRP, which is another marker of sys-
temic inflammation, displayed no significant differences in the HRR(1 min) and HRR(2 min)
groups (HRR[1 min], 1.54 ± 1.56 mg/L vs. 1.55 ± 1.51 mg/L, p = 0.978; HRR[2 min], 1.80 ±
1.52 mg/L vs. 1.38 ± 1.48 mg/L, p = 0.232). Serum levels of MIG and hsCRP according to HRR
in ADHF patients are shown in Fig 1.
Regarding the prognostic value of HRR, both low HRR(1 min) (< 13) and HRR(2 min)
(< 27), were shown to be associated with poor clinical outcome (p = 0.001 for HRR[1 min],
p = 0.006 for HRR[2 min]) in a Kaplan-Meier analysis (Fig 2).
To determine which factors are relevant to the clinical outcome of ADHF patients, we stud-
ied univariate and multivariate analysis for CV events. Due to the small number of CV events,
we performed both enter method and stepwise method multivariate Cox regression analysis in
this study (Table 2).
In enter method multivariate Cox regression analysis, both HRR(1min) (p = 0.033) and
HRR(2min) (p = 0.039) showed independent prognostic value when controlled for age, types
of heart failure, BMI, hemoglobin, NT-proBNP, and beta-blocker use. Stepwise method multi-
variate Cox regression analysis also revealed independent association of both HRR(1min)
(p = 0.018) and HRR(2min) (p = 0.021) with the clinical outcome even after adjusting the most
relevant minimum variables (age, types of heart failure and BMI) to avoid the over-fitting.
In the likelihood ratio test, the full model with HRR(1 min) or HRR(2 min) exhibited signif-
icantly lower –2 log likelihood than the reduced model without HRR in both enter method
(HRR[1 min], 180.827 vs. 195.486, p<0.001; HRR[2 min], 191.154 vs. 195.486, p = 0.037) and
stepwise method (HRR[1 min], 209.009 vs. 225.768, p<0.001; HRR[2 min], 220.303 vs.
225.768, p = 0.019). Time-dependent ROC curves also demonstrated that the concordance
probability (iAUC) increased from 0.756 (reduced model without HRR) to 0.787 (full model
Impaired Heart Rate Recovery in ADHF
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Table 1. Clinical characteristics, echocardiographic, laboratory and cardiopulmonary exercise test parameters according to CV events in study
subjects.
CV events (N = 30, 28.0%) No CV event (N = 77, 72.0%) P-value
Age (years) 62 ± 15 58 ± 15 0.203
Male gender (N, %) 17 (56.7%) 54 (70.1%) 0.137
Ischemic aetiology (N, %) 8 (26.7%) 17 (22.1%) 0.394
De novo HF (N, %) 11 (36.7%) 57 (74.0%) <0.001
Hypertension (N, %) 13 (43.3%) 38 (49.4%) 0.576
Diabetes (N, %) 12 (40.0%) 30 (39.0%) 0.921
BMI (kg/m2) 22.7 ± 2.9 24.7 ± 3.8 0.008
Echocardiographic parameters
LVEF (%) 30.3 ± 15.1 28.4 ± 14.0 0.548
LVMI (g/m2) 148.2 ± 54.1 145.8 ± 35.3 0.796
LAVI (mL/m2) 63.2 ± 33.4 55.3 ± 20.7 0.143
E/E’ 23.3 ± 13.0 24.5 ± 11.6 0.687
Laboratory parameters
WBC (×103/μL) 7182 ± 3640 7526 ± 2769 0.599
Ln hsCRP (mg/L) 1.51 ± 1.87 1.55 ± 1.32 0.915
Haemoglobin (g/dL) 12.1 ± 2.7 13.7 ± 2.6 0.007
Sodium (mmol/L) 138.7 ± 3.5 139.5 ± 4.8 0.437
Cholesterol (mg/dL) 144.5 ± 39.8 155.6 ± 43.4 0.233
Albumin (g/dL) 3.8 ± 0.5 3.8 ± 0.4 0.416
eGFR (mL/min/1.73 m2) 65.0 ± 26.6 69.8 ± 22.5 0.370
Ln NT-proBNP (pg/mL) 8.33 ± 0.84 7.86 ± 1.10 0.049
Markers for pro-inﬂammatory response
Ln MIG (pg/mL) 7.32 ± 1.23 6.86 ± 1.02 0.113
Ln IP-10 (pg/mL) 5.92 ± 0.52 5.80 ± 0.62 0.425
Ln CX3CL1 (pg/mL) 3.85 ± 0.15 3.83 ± 0.17 0.730
Ln MCP1 (pg/mL) 4.52 ± 0.42 4.37 ± 0.54 0.235
Ln MIP1α (pg/mL) 2.17 ± 1.04 2.19 ± 1.30 0.937
Ln MIP1β (pg/mL) 4.34 ± 1.01 4.71 ± 0.93 0.145
Ln RANTES (pg/mL) 9.04 ± 0.13 9.03 ± 0.18 0.898
Ln Granzyme B (pg/mL) 3.73 ± 0.21 3.74 ± 0.27 0.933
Ln TNFα (pg/mL) 2.27 ± 0.40 2.28 ± 0.35 0.982
Medications at discharge
RAS blockers (N, %) 23 (76.7%) 64 (83.1%) 0.305
Beta-blockers (N, %) 10 (33.3%) 53 (68.8%) 0.001
Aldosterone antagonist (N, %) 22 (73.3%) 64 (83.1%) 0.190
Calcium channel blockers (N, %) 2 (6.7%) 7 (9.1%) 0.513
Digoxin (N, %) 9 (30.0%) 14 (18.2%) 0.142
Exercise parameters
Peak VO2 (mL/kg/min) 15.2 ± 5.4 20.0 ± 5.9 <0.001
Exercise duration (sec) 306 ± 206 505 ± 213 <0.001
Aerobic threshold time (sec) 149 ± 113 309 ± 177 <0.001
VE/VCO2 slope 45.6 ± 10.4 37.6 ± 9.2 <0.001
Baseline heart rate (bpm) 83.4 ± 17.9 82.7 ± 14.2 0.861
Peak heart rate (bpm) 121.8 ± 26.3 138.6 ± 30.8 0.010
HRR(1 min) 6.7 ± 10.2 19.1 ± 18.2 <0.001
(Continued)
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Table 1. (Continued)
CV events (N = 30, 28.0%) No CV event (N = 77, 72.0%) P-value
HRR(2 min) 25.9 ± 17.4 37.7 ± 22.1 0.010
Values are mean ± SD or number (%). CV, cardiovascular; HF, heart failure; BMI, body mass index; LVEF, left ventricular ejection fraction; LVMI, left
ventricular mass index; LAVI, left ventricular volume index; WBC, white blood cell; hsCRP, high sensitive C-reactive protein; eGFR, estimated glomerular
ﬁltration rate; NT-proBNP, N-terminal of the prohormone brain natriuretic peptide; MIG, monokine-induced by gamma interferon; IP-10, interferon gamma-
induced protein 10; CX3CL1, chemokine (C-X3-C motif) ligand 1; MCP1, monocyte chemotactic protein 1; MIP1α, macrophage inﬂammatory protein 1α;
MIP1β, macrophage inﬂammatory protein 1β; RANTES, regulated on activation normal T cell expressed and secreted; TNF-α, tumour necrosis factor-α;
RAS, renin angiotensin aldosterone system; HRR, heart rate recovery. Discrete variables were compared using the chi-squared method, and independent
Student’s t-tests were applied for the continuous variables.
doi:10.1371/journal.pone.0154534.t001
Fig 1. Serum levels of MIG and hsCRP according to HRR in ADHF patients.
doi:10.1371/journal.pone.0154534.g001
Fig 2. Cumulative Kaplan-Meier estimates of CV events according to HRR in ADHF patients.
doi:10.1371/journal.pone.0154534.g002
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with HRR[1 min]) or 0.778 (full model with HRR[2 min]) in enter method and from 0.746
(reduced model without HRR) to 0.785 (full model with HRR[1 min]) or 0.774(full model with
HRR[2 min]) in stepwise method. Visual inspection revealed that the full model had a higher
iAUC throughout the entire follow-up period than the reduced model in both enter and step-
wise method (Fig 3).
To calculate the difference in iAUC between the full and reduced models, bootstrap resam-
pling tests were performed 1,000 times. The difference (iAUC of full model—iAUC of reduced
model) was statistically significant both for HRR(1 min) (estimated difference was 0.030, 95%
CI is 0.001–0.086) and HRR(2 min) (estimated difference was 0.021, 95% CI is 0.001–0.066) in
enter method and also significant both for HRR(1 min) (estimated difference was 0.039, 95%
CI is 0.001–0.107) and HRR(2 min) (estimated difference was 0.028, 95% CI is 0.001–0.091) in
stepwise method. These findings suggest that the addition of both HRR(1 min) and HRR
(2min) to the model increases the predictive accuracy for CV events.
Discussion
The results of this study demonstrate that post-exercise HRR, which is an index of parasympa-
thetic function, is associated with increased MIG level and independently predicts clinical out-
come in prospectively and consecutively enrolled, recovered ADHF patients even after
adjustment for age, types of heart failure, BMI, hemoglobin, NT-proBNP, and beta-blocker
use. Moreover, the addition of HRR to a model significantly increased the predictability for CV
events across the entire follow-up period.
The significant association between impaired HRR and adverse clinical outcome has been
consistently reported in subjects referred for exercise testing regardless of cardiovascular dis-
ease history [3–5] and in patients with chronic heart failure [6–11]. However, the potential for
Table 2. Univariate andmultivariate Cox regression analysis for CV events in patients with ADHF.
CV events Univariate Enter method multivariate Stepwise method multivariate
with HRR(1min) with HRR(2min) with HRR(1min) with HRR(2min)
HR (95% CI) P-
value
HR (95% CI) P-
value
HR (95% CI) P-
value
HR (95% CI) P-
value
HR (95% CI) P-
value
Age 1.017 (0.992–
1.043)
0.178 0.998 (0.967–
1.029)
0.882 0.986 (0.957–
1.015)
0.327 1.009 (0.982–
1.036)
0.527 0.997 (0.971–
1.023)
0.800
De novo HF 0.255 (0.121–
0.537)
<0.001 0.346 (0.131–
0.916)
0.033 0.360 (0.145–
0.890)
0.027 0.303 (0.138–
0.666)
0.003 0.317 (0.147–
0.686)
0.004
BMI 0.828 (0.728–
0.943)
0.004 0.879 (0.749–
1.031)
0.114 0.857 (0.724–
1.014)
0.072 0.867 (0.760–
0.988)
0.033 0.827 (0.718–
0.952)
0.008
Hemoglobin 0.801 (0.693–
0.924)
0.002 1.008 (0.799–
1.272)
0.947 0.951 (0.766–
1.182)
0.652
Ln NT-proBNP 1.535 (1.041–
2.262)
0.030 1.108 (0.691–
1.779)
0.670 1.027 (0.658–
1.603)
0.906
Beta-blocker
use
0.258 (0.120–
0.555)
0.001 0.581 (0.180–
1.873)
0.363 0.582 (0.199–
1.700)
0.322
HRR(1 min) 0.273(0.117–
0.639)
0.003 0.354 (0.136–
0.921)
0.033 0.354 (0.149–
0.839)
0.018
HRR(2 min) 0.384(0.186–
0.791)
0.009 0.400 (0.167–
0.957)
0.039 0.396 (0.180–
0.869)
0.021
CV, cardiovascular; HR, hazard ratio; CI, conﬁdence interval; HF, heart failure; BMI, body mass index; NT-proBNP, N-terminal of the prohormone Brain
Natriuretic Peptide; HRR, heart rate recovery.
doi:10.1371/journal.pone.0154534.t002
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referral bias exists because most of the cohorts investigated in previous studies were selected
from an exercise test database. Therefore, we evaluated its prognostic value in prospectively
and consecutively enrolled, recovered ADHF patients during a specific study period. Moreover,
we aimed to determine the underlying mechanism that leads to a poor clinical outcome in
patients with impaired HRR in terms of an exaggerated pro-inflammatory response.
The pathophysiology of how impaired autonomic dysfunction in heart failure contributes
to poor clinical outcome remains poorly understood. One contributing factor could be that
parasympathetic dysfunction, which is indicated by impaired HRR, might be related with
excessive pro-inflammatory status. The discovery of a pathway in which cholinergic neurons
inhibit exaggerated inflammation has expanded our understanding of how nervous system
modulates immune responses. The nervous system reflexively regulates the inflammatory
response in real time, just as it controls the heart rate and other vital functions. Immunity is
coordinated by neural circuits that operate reflexively. This well-established neural circuit ter-
minates excessive pro-inflammatory cytokine responses, preventing immune-mediated dam-
age [12,13]. Therefore, decreased parasympathetic activity may result in exaggerated pro-
inflammatory responses and increased morbidity and mortality [14–16]. However, there is a
possibility that higher inflammation levels may result in impaired parasympathetic function as
well.
Various markers for the pro-inflammatory response, including serum chemokine markers,
granzyme B, and TNF-α, as well as hsCRP, were evaluated in this study. Among them, MIG,
which is one of the C-X-C chemokine receptor type 3 (CXCR3)-binding T cell chemokines,
showed significant differences across the HRR groups unlike hsCRP and TNF-α. Recent
human studies reported that circulating MIG levels are increased in newly diagnosed, treat-
ment-naïve hypertensive patients [18], and are independently associated with the coronary
artery calcium score [19] or carotid intima media thickness [20]. Recently, the pathogenic role
Fig 3. Time-dependent receiver operating curve analysis derived from the Cox regression models with and without HRR(1min) and HRR(2min)
in enter method (A) and in stepwise method (B). The area under the curve (AUC) indicated predictive accuracy at the indicated time. Throughout the
study period, the model with HRR was superior to the model without HRR in distinguishing patients who will exhibit CV events from those who will not.
doi:10.1371/journal.pone.0154534.g003
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of CD4+ T cells in pressure overload-induced cardiac remodelling and in the transition to heart
failure was demonstrated in animal models [21]. Moreover, the enhanced CD4+ T cell activa-
tion observed in patients with heart failure in proportion to severity suggests that T cell-driven
inflammation is one important pathophysiology of heart failure [22,23]. Consequently, our
findings that patients with autonomic dysfunction showed increased serumMIG levels further
support the involvement of T cell-driven inflammation in patients with heart failure.
It has been suggested that specific medication, such as beta-blockers, may influence the
HRR. Lipinski, et al. [7] and Kubrychtova, et al. [10] showed improved HRR in patients taking
beta-blockers while Racine, et al. [24] reported that beta-blocker therapy does not significantly
improve HRR, suggesting that controlling for beta-blocker use in the evaluation of HRR may
not be necessary. In our study, both HRR(1 min) and HRR(2 min) showed no significant dif-
ferences between beta-blocker users and non-users. However, impaired post-exercise HRR
independently predicted clinical outcome irrespective of beta-blocker use in this study.
Several device-based therapies to target specific aspects of autonomic imbalance are actively
under investigation in patients with heart failure. Among them, vagal nerve stimulation has
been shown to improve clinical heart failure symptoms, New York Heart Association (NYHA)
heart failure class, and evidence of left ventricular reverse remodelling in an open label pilot
study [25]. More recently, the results of two other human vagal nerve stimulation studies,
NECTAR-HF [26] and ANTHEM-HF [27], were reported. While NECTAR-HF did not show
improvements in the primary endpoint of reduction in left ventricular end-systolic diameter
(LVESD), ANTHEM-HF demonstrated significant improvement in left ventricular ejection
fraction and LVESD in left and right vagal stimulation of chronic symptomatic heart failure
patients. Currently, the INOVATE HF clinical trial [28], using the CardioFit System, is being
conducted in 90 centres worldwide to evaluate its long-term safety and efficacy in patients.
This trial will provide more definitive data on the safety and efficacy of vagal nerve stimulation
in patients with heart failure. Another recent first-in-human trial of high thoracic spinal cord
stimulation revealed that this approach is safe and can potentially improve symptoms, func-
tional capacity, and cardiac function in patients with advanced HF [29]. Regarding the use of
device-based therapies to modulate autonomic dysfunction, it is important to investigate the
proper patient population, one that will benefit from these device therapies. Post-exercise
HRR, which is an index of parasympathetic function, can be used in patient selection for auto-
nomic modulation similar to left bundle branch block pattern QRS morphology and QRS dura-
tion for cardiac resynchronization therapy.
The present study has several potential limitations. First, due to the maximal exercise proto-
col, the intensity of exercise by each patient is not controlled. Second, our study population
cannot represent all heart failure patients. The analysed subjects were hospitalized and ambula-
tory, recovered ADHF patients. Moreover, these data were collected from a Korean population.
The generalizability of the current findings to other populations (e.g. Caucasian populations) is
unknown. Third, the lack of adjustment for diet pattern and socioeconomic status might be
noted as well. Fourth, due to the small number of CV events, our multivariate Cox regression
model included a limited number of variables. Peak VO2, which is a well-known prognostic
factor in patients with HF is not adjusted in the multivariate analysis due to the significant co-
linearity with both HRR(1 min) and HRR(2 min). Finally, lack of other parasympathetic activ-
ity measurements, such as heart rate variability or baroreflex sensitivity, could be another limi-
tation of this study. However, we evaluated the prognostic value of post-exercise HRR in
prospectively and consecutively enrolled, recovered ADHF patients, thereby minimizing the
potential for referral bias. Moreover, we sought to examine the underlying mechanism that
leads to poor clinical outcome in patients with impaired HRR in terms of ‘cholinergic anti-
inflammatory pathway’.
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Conclusions
Post-exercise HRR is an index of parasympathetic function associated with clinical outcome in
patients with chronic heart failure. However, its prognostic value has not been confirmed in
prospectively and consecutively enrolled ADHF patients. Here, we confirm that impaired post-
exercise HRR is associated with an exaggerated pro-inflammatory response and independently
predicts clinical outcome in patients with ADHF. Measurement of post-exercise HRR is a sim-
ple and feasible assessment, which might have important implications on risk stratification of
ADHF patients.
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